Pharmaceutical News

RSS

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

AbGenomics International announced today that it has raised $9.6 million in current financing round.

18 Jul 2013

Single dose of methylphenidate can reduce risk of falls among elderly adults

Ben-Gurion University of the Negev researchers have discovered that a single dose of methylphenidate, used to treat Attention Deficit Hyperactivity Disorder and narcolepsy, helps to improve balance control during walking, hence reducing the risk of falls among elderly adults.

18 Jul 2013

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain.

17 Jul 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.

17 Jul 2013

Scientists develop statistical models to predict which drug is best for specific disease

Medicines that are personally tailored to your DNA are becoming a reality, thanks to the work of U.S. and Chinese scientists who developed statistical models to predict which drug is best for a specific individual with a specific disease.

17 Jul 2013

North Dakota judge strikes down state law on nonsurgical abortion drugs

The state judge issues an opinion from an April trial. In the meantime, new abortion and "personhood" proposals in that state rankle some medical professionals.

17 Jul 2013

Vitamin and mineral supplements can enhance mental energy and well-being

Vitamin and mineral supplements can enhance mental energy and well-being not only for healthy adults but for those prone to anxiety and depression, according to a July 15 panel discussion at the 2013 Institute of Food Technologists (IFT) Annual Meeting & Food Expo- held at McCormick Place.

17 Jul 2013

Drug to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy

A drug already approved to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy, or thickening of the cardiac muscle--a disorder that often leads to heart failure, researchers at the University of Illinois at Chicago College of Medicine report.

17 Jul 2013

Study demonstrates effectiveness of everolimus for TSC patients

A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce seizures in patients with tuberous sclerosis complex - a genetic disease characterized by benign tumors on multiple organ systems.

16 Jul 2013

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.

16 Jul 2013

Actavis’ Lamictal ODT drug receives FDA approval for treatment of epilepsy and bipolar disorder

Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Lamotrigine Orally Disintegrating Tablets, 25 mg, 50 mg, 100 mg and 200 mg, a generic equivalent to GlaxoSmithKline's Lamictal® ODT.

16 Jul 2013

Study explores mechanisms of chemotherapy-induced neurological side effects

Chemotherapy is one of the primary treatments for cancer. However, one of the most disturbing findings of recent studies of cancer survivors is the apparent prevalence of chemotherapy-associated adverse neurological effects, including vascular complications, seizures, mood disorders, cognitive dysfunctions, and peripheral neuropathies.

16 Jul 2013

New influenza vaccine options for upcoming flu season

The next flu shot season will include several new vaccine options for consumers, Mayo Clinic vaccine expert Gregory Poland, M.D., says. Fearful of needles? There's now an influenza vaccination just for you. Allergic to eggs? It won't stop you from getting a flu shot. The new choices move influenza vaccinations closer to the personalized approach long sought by immunologists including Dr. Poland, but they may also prove bewildering to patients, he says.

16 Jul 2013

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Companion test also approved to identify appropriate patients The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Lung cancer is the leading cause of cancer-related death among men and women.

16 Jul 2013

Protein complex may be an effective alternative to opioid pain medications

A drug targeting a protein complex containing two different types of opioid receptors may be an effective alternative to morphine and other opioid pain medications, without any of the side effects or risk of dependence, according to research led by the Icahn School of Medicine at Mount Sinai.

16 Jul 2013

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer Inc. announced today that tofacitinib has been approved for the treatment of rheumatoid arthritis in patients who had an inadequate response to existing therapies in several additional countries around the world, including Switzerland, which is the first European country to receive approval.

15 Jul 2013

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

15 Jul 2013

Actavis receives FDA approval for Opana ER tablets

Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-release Tablets, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg.

15 Jul 2013

FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.

From QIAGEN Manchester Limited 15 Jul 2013

TSRI scientists design drug candidate that increases exercise endurance in animal models

An international group of scientists has shown that a drug candidate designed by scientists from the Florida campus of The Scripps Research Institute (TSRI) significantly increases exercise endurance in animal models.

15 Jul 2013

Pharmaceutical News

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

Single dose of methylphenidate can reduce risk of falls among elderly adults

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Scientists develop statistical models to predict which drug is best for specific disease

North Dakota judge strikes down state law on nonsurgical abortion drugs

Vitamin and mineral supplements can enhance mental energy and well-being

Drug to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy

Study demonstrates effectiveness of everolimus for TSC patients

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Actavis’ Lamictal ODT drug receives FDA approval for treatment of epilepsy and bipolar disorder

Study explores mechanisms of chemotherapy-induced neurological side effects

New influenza vaccine options for upcoming flu season

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Protein complex may be an effective alternative to opioid pain medications

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

Actavis receives FDA approval for Opana ER tablets

FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients

TSRI scientists design drug candidate that increases exercise endurance in animal models

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News